Tata Capital’s PE fund raises Rs 955 cr to be invested in pharma, healthcare sectors

Mumbai: Tata Capital on Monday announced a Rs 955 crore fundraise by a private equity arm for investing in healthcare companies. The Tata Capital Healthcare Fund II (TCHF II) achieved a final closure of its fund with investor commitments of Rs 955 crore or USD 126 million, a statement by Tata Capital said.

The offering is a follow-up to the Tata Capital Healthcare Fund I which had raised Rs 411 crore in 2012.

The second fund has garnered commitments from domestic and international financial and strategic institutions including some of the global pharma, medical equipment companies, development financial institutions and large European institutions, it said, adding Government of India has also committed money through the Self Reliant India fund.

TCHF II will principally be taking equity positions in healthcare and life sciences related companies having significant business exposure to India, its managing partner Visalakshi Chandramouli said.

About 60 per cent of the new fund’s bets will be focused on the theme of domestic healthcare and life sciences consumption, while the rest will be devoted to companies focused on healthcare and life sciences competency through delivering products or services to the world markets, Chandramouli elaborated.

The new fund has already committed money to three companies namely Linux Pharma (domestic pharma formulations), Atulaya Healthcare (diagnostic services) and Deeptek Inc (digital health), and expects to announce the fourth investment shortly, its partner Vamesh Chovatia added.

It has a pipeline of deals and is expected to continue the deal momentum in the coming months, Chovatia said, adding, it is typically looking at committing USD 5-15 million per transaction and potentially a larger ticket size along with co-investment support from its limited partners, who have committed to investing in the fund. PTI AA

  • Related Posts

    Alembic Pharma Secures USFDA Approval for Generic Synthroid Tablets

    New Delhi: Alembic Pharmaceuticals has received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Levothyroxine Sodium Tablets USP in…

    STF busts fake meds racket spread across 6 states

    Dehradun: Uttarakhand special task force (STF) on Friday busted an online fake medicine racket operating through a Facebook page that allegedly sold counterfeit drugs, including cancer medicines, at discounts of…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Alembic Pharma Secures USFDA Approval for Generic Synthroid Tablets

    Alembic Pharma Secures USFDA Approval for Generic Synthroid Tablets

    STF busts fake meds racket spread across 6 states

    STF busts fake meds racket spread across 6 states

    All the Way from Teeth to Tee: Hole in One

    All the Way from Teeth to Tee: Hole in One

    Zydus Lifesciences Q4FY26 net profit rises 9%

    Zydus Lifesciences Q4FY26 net profit rises 9%

    Chemists strike on May 20: Reasons behind today’s all-India strike

    Chemists strike on May 20: Reasons behind today’s all-India strike

    AbbVie loses patent plea for Hep C drug

    AbbVie loses patent plea for Hep C drug